Preparation and characterization of Ga-68-deferoxamine to test the feasibility as a bifunctional chelating agent or a renal imaging radiopharmaceutical

다국어 초록 (Multilingual Abstract)

Chelating agents 1,4,7-triazacyclononanetriacetic acid (NOTA), 1,4,7,10-tetraazacyclododecane-1,4,7,10- tetraacetic acid (DOTA) and 30-amino-3,14,25-trihydroxy-3,9,14,20,25-penta-azatriacontane-2,10,13, 21,24-pentaone (desferrioxamine, DFO) were labeled with 68Ga and tested in vitro properties to check the feasibility of using DFO as a bifunctional chelating agent or renal imaging agent. The chelating agents of concentration 2 μM were labeled with 68Ga in 0.1 M HCl at pH 1.7-10.3 at room temperature and 80℃ and the optimal pH for labeling each chelating agent was found. And then, the chelating agents were labeled with 68Ga in various concentration of chelating agents at optimal pH. The labeled chelating agents were subject to stability test in human serum and to binding studies to human red blood cell (RBC) and plasma protein. The optimal pH’s of NOTA, DOTA and DFO for 68Ga-labeling were 4.4, 3.6 and 5.6, respectively. DFO (10 μM) showed high labeling efficiency (>97%) at pH 5.6. All the labeled chelating agents showed high stability in human serum. 68Ga-DFO showed low RBC binding but significant amount was bound to plasma protein. The results demonstrated that 68Ga-DFO can be used as a bifunctional chelating agent but not as a renal imaging agent. J Radiopharm Mol Probes 1(1):31-37, 2015

참고문헌 (Reference)

1 정재민, "양전자 방출핵종 68Ga을 이용한 NOTA와 DOTA의 표지 및 시험관내 특성 연구" 대한핵의학회 43 (43): 330-336, 2009

2 Milliner DS, "Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy" 101 : 775-780, 1984

3 Parker D, "Tumor targeting with radiolabeled macrocycle antibody conjugates" 19 : 271-291, 1990

4 Breeman WA, "The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?" 34 : 978-981, 2007

5 Studer M, "Synthesis of novel 1,4,7-triazacyclononane-N,N',N"-triacetic acid derivatives suitable for protein labeling" 3 : 337-341, 1992

6 Qi Z, "Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance" 286 : F590-F596, 2004

7 Cappellini MD, "Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia" 29 : 909-917, 2007

8 Zhernosekov KP, "Processing of generator-produced 68Ga for medical application" 48 : 1741-1748, 2007

9 Jeong JM, "Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice" 49 : 830-836, 2008

10 Lee JY, "Preparation of Ga-68-NOTA as a renal PET agent and feasibility tests in mice" 41 : 210-215, 2014

11 Roesch F, "Maturation of a key resource - the germanium-68/gallium-68 generator: development and new insights" 5 : 202-211, 2012

12 Yang BY, "Formulation of 68Ga BAPEN kit for myocardial positron emission tomography imaging and biodistribution study" 37 : 149-155, 2010

13 Choi JY, "Development of 68Ga-labeled mannosylated human serum albumin (MSA) as a lymph node imaging agent for positron emission tomography" 38 : 371-379, 2011

14 Hernandez P, "Deferoxamine for aluminum toxicity in dialysis patients" 17 : 224-228, 1990

15 Stacy BD, "Chromium-51 ethylenediaminetetraacetate for estimation of glomerular filtration rate" 152 : 1076-1077, 1966

16 Giardina PJ, "Chelation-therapy in beta-thalassemia: the benefits and limitations of desferrioxamine" 32 : 304-312, 1995

17 Greene MW, "An improved gallium-68 cow" 12 : 62-63, 1961

18 Shetty D, "68Ga-labeled radiopharmaceuticals for positron emission tomography" 44 : 233-240, 2010